Drugs / EDP-322
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00990145 | Nov 2008 → Mar 2009 | methicillin-resistant staphylococcus aureus infectious disease | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT00989872 | — | methicillin-resistant staphylococcus aureus infectious disease, necrotizing soft tissue infection | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP-322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00990145 ↗ |
| Route | Oral | “orally administered EDP-322” NCT00989872 ↗ |